Author

Shingo Kuroda

Observed names: S Kuroda, S. Kuroda

Observed institutions: Sanofi (Japan), Takeda (Japan)

ORCID: 0000-0001-7672-4214

Observed ORCID: 0000-0001-7672-4214

OpenAlex ID: A5017301749

Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study

2015 · Nobuya Inagaki, Hitoshi Onouchi, et al. · The Lancet Diabetes & Endocrinology · 89

SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

2013 · Nobuya Inagaki, Hitoshi Onouchi, et al. · The Lancet Diabetes & Endocrinology · 56

Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients

2020 · Yoshihiko Tomita, Katsunori Tatsugami, et al. · International Journal of Urology · 30

PDF

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study

2021 · Masatoshi Kudo, Kaoru Tsuchiya, et al. · Journal of Gastroenterology · 27

PDF

Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study

2016 · Nobuya Inagaki, Hiroki Sano, et al. · Journal of Diabetes Investigation · 19

PDF

Efficacy and safety of once‐weekly oral trelagliptin switched from once‐daily dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: An open‐label, phase 3 exploratory study

2017 · Nobuya Inagaki, Hiroki Sano, et al. · Journal of Diabetes Investigation · 17

PDF

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

2021 · Xiaofei Zhou, Sharon Friedlander, et al. · Clinical and Translational Science · 15

PDF

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

2014 · H. Murakami, T. Kurata, et al. · Cancer Chemotherapy and Pharmacology · 10

PDF

Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3 study

2025 · Zhiqiang Song, Qin Du, et al. · Chinese Medical Journal · 9

Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study

2018 · Kohei Kaku, Shingo Kuroda, et al. · Diabetes Obesity and Metabolism · 9

PDF

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study

2023 · Naoya Kato, Masatoshi Kudo, et al. · Hepatology Research · 7

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma

2023 · Noboru Nakaigawa, Yoshihiko Tomita, et al. · International Journal of Clinical Oncology · 7

PDF

Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria

2019 · Sadayoshi Ito, Tomoya Kagawa, et al. · Clinical Journal of the American Society of Nephrology · 7

A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma.

2020 · Mototsugu Oya, Satoshi Tamada, et al. · Journal of Clinical Oncology · 6

Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects

2018 · Kumi Matsuno, Shingo Kuroda, et al. · Basic & Clinical Pharmacology & Toxicology · 4

PDF

Sa1365 A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VONOPRAZAN-BASED VERSUS ESOMEPRAZOLE-BASED BISMUTH-CONTAINING QUADRUPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI INFECTION IN CHINA

2023 · Zhiqiang Song, Qin Du, et al. · Gastroenterology · 3

PDF

Mo020safety, Tolerability, Pharmacokinetics (pk), and Pharmacodynamics (pd) of Single Doses of Tak-272, a Novel Renin Inhibitor, in Healthy Male Subjects

2017 · K Matsuno, S Kuroda, et al. · Nephrology Dialysis Transplantation · 3

PDF

Post‐Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma

2026 · Hiro‐omi Kanayama, Shingo Kuroda, et al. · International Journal of Urology · 1

Exploratory Biomarker Analysis in the Ph 3 Echelon‐1 Study: Worse Outcome With Abvd in Patients With Elevated Baseline Levels of Scd30 and Tarc

2019 · J. Radford, J.M. Connors, et al. · Hematological Oncology · 1

PDF

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

2026 · Yayoi Tada, Yoshiko Maeda, et al. · The Journal of Dermatology

Principal quantile treatment effect estimation using principal scores

2024 · Kotaro Mizuma, Takamasa Hashimoto, et al. · Statistics in Medicine

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

2018 · Yukio Shimasaki, Masashi Sakaki, et al. · Clinical Drug Investigation

PDF

SaO008THE EFFICACY AND SAFETY OF IMARIKIREN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND MICROALBUMINURIA: A RANDOMIZED, MULTI CENTER, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL

2018 · Sadayoshi Ito, Tomoya Kagawa, et al. · Nephrology Dialysis Transplantation

PDF

Contributors

2013 · Shingo Kuroda, Matthieu Schmittbuhl, et al. · Elsevier eBooks

Works count: 24

Citation count: 320

H-index: 9

I10-index: 8